AP Biosciences Income Statement

Financials in millions TWD. Fiscal year is January - December.

Millions TWD. Fiscal year is Jan - Dec.

Fiscal Year	TTM	FY 2024	FY 2023	FY 2022
Period Ending	Sep '25 Sep 30, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022
Revenue	-	-	32.25	-
Gross Profit	-	-	32.25	-
Selling, General & Admin	82.63	73.11	43.13	34.82
Research & Development	375.7	365.95	336.6	262.68
Operating Expenses	458.33	439.06	379.73	297.5
Operating Income	-458.33	-439.06	-347.48	-297.5
Interest Expense	-1.48	-1.65	-1.2	-
Interest & Investment Income	19.4	13.52	10.03	2.58
Currency Exchange Gain (Loss)	-5	4.26	-0.83	6.27
Other Non Operating Income (Expenses)	0.11	0.18	0.19	0.11
EBT Excluding Unusual Items	-445.3	-422.75	-339.29	-288.54
Gain (Loss) on Sale of Assets	-	-	-0	-
Pretax Income	-447.41	-422.75	-339.3	-288.54
Net Income	-447.41	-422.75	-339.3	-288.54
Net Income to Common	-447.41	-422.75	-339.3	-288.54
Shares Outstanding (Basic)	85	75	65	53
Shares Outstanding (Diluted)	85	75	65	53
Shares Change (YoY)	21.09%	16.28%	22.98%	-
EPS (Basic)	-5.26	-5.61	-5.24	-5.48
EPS (Diluted)	-5.26	-5.61	-5.24	-5.48
Free Cash Flow	-382.21	-363.41	-332.65	-277.1
Free Cash Flow Per Share	-4.49	-4.83	-5.14	-5.26
Gross Margin	-	-	100.00%	-
Operating Margin	-	-	-1077.35%	-
Profit Margin	-	-	-1051.98%	-
Free Cash Flow Margin	-	-	-1031.37%	-
EBITDA	-446.74	-433.93	-344.01	-290.07
D&A For EBITDA	11.59	5.13	3.46	7.42
EBIT	-458.33	-439.06	-347.48	-297.5

Updated Jun 30, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.